Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.67
-1.8%		$0.71
$0.55
▼
$1.79
$8.46M1.5250,388 shs21,281 shs
BioVie Inc. stock logo
BIVI
BioVie
$1.56
$1.70
$0.82
▼
$3.79
$11.77M0.67.28 million shs4.83 million shs
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.22
-6.8%		$4.09
$3.13
▼
$7.20
$6.63M1.1822,785 shs28,389 shs
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+3.47%+9.98%-5.40%-27.42%-59.82%
BioVie Inc. stock logo
BIVI
BioVie
+22.83%-23.53%-4.88%+13.04%-6.59%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-13.32%-11.99%-8.73%-31.00%-37.27%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-93.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.67
-1.8%		$0.71
$0.55
▼
$1.79
$8.46M1.5250,388 shs21,281 shs
BioVie Inc. stock logo
BIVI
BioVie
$1.56
$1.70
$0.82
▼
$3.79
$11.77M0.67.28 million shs4.83 million shs
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.22
-6.8%		$4.09
$3.13
▼
$7.20
$6.63M1.1822,785 shs28,389 shs
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+3.47%+9.98%-5.40%-27.42%-59.82%
BioVie Inc. stock logo
BIVI
BioVie
+22.83%-23.53%-4.88%+13.04%-6.59%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-13.32%-11.99%-8.73%-31.00%-37.27%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-93.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.40
Hold$3.07357.03% Upside
BioVie Inc. stock logo
BIVI
BioVie
1.00
SellN/AN/A
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.40
Hold$34.67977.94% Upside
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest CLSD, BIVI, APRE, and BOLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$3.00
7/17/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
BioVie Inc. stock logo
BIVI
BioVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
5/28/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Rodman & Renshaw logo
Rodman & Renshaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$22.00
5/28/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
5/14/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$7.00 ➝ $6.00
(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$290K28.64N/AN/A$1.52 per share0.44
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$9.93 per shareN/A
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$6.50M0.95N/AN/A$13.81 per share0.23
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$3.33M0.64N/AN/A($7.68) per share-0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.60M-$1.54N/AN/AN/A-4,405.59%-56.85%-47.42%N/A
BioVie Inc. stock logo
BIVI
BioVie
-$17.54M-$2.45N/AN/AN/AN/A-101.15%-90.18%8/24/2026 (Estimated)
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$33.38M-$16.44N/AN/AN/A-611.47%-109.93%-50.77%N/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$34.35M-$5.19N/AN/AN/A-665.19%N/A-124.15%N/A

Latest CLSD, BIVI, APRE, and BOLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/24/2026Q4 2026
BioVie Inc. stock logo
BIVI
BioVie
-$0.52N/AN/AN/AN/AN/A
8/12/2026Q2 2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.1775-$0.07+$0.1075-$0.07$0.25 millionN/A
8/12/2026Q4 2026
BioVie Inc. stock logo
BIVI
BioVie
N/A-$0.70N/A-$0.70N/AN/A
8/11/2026Q2 2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$3.39-$4.57-$1.18-$4.57$0.50 million$0.01 million
5/13/2026Q1 2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
8.92
8.92
BioVie Inc. stock logo
BIVI
BioVie
N/A
9.96
9.96
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.98
3.51
3.51
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
3.87
3.87

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
BioVie Inc. stock logo
BIVI
BioVie
4.59%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
10.49%
BioVie Inc. stock logo
BIVI
BioVie
0.90%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
9.40%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
712.38 million11.08 millionNo Data
BioVie Inc. stock logo
BIVI
BioVie
107.54 million7.48 millionNo Data
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
901.92 million1.74 millionNot Optionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
305.23 million4.89 millionOptionable

Recent News About These Companies

Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260714817142/en/clearside-biomedical-inc.-completes-financial-restructuring-and-emerges-from-chapter-11-with-steel-partners-as-plan-sponsor/
Clearside Biomedical Faces Delisting After Bankruptcy Filing
November 25, 2025  |  msn.comhttps://www.msn.com/en-us/money/technology/clearside-biomedical-faces-delisting-after-bankruptcy-filing/ar-AA1R9ZAu
Clearside Biomedical to pursue sale of business via Chapter 11 process
November 24, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/clearside-biomedical-to-pursue-sale-of-business-via-chapter-11-process/ar-AA1R3qlu
Clearside Biomedical, Inc. Files Chapter 11 Bankruptcy to Pursue Asset Sale and Maximize Stakeholder Value
November 24, 2025  |  quiverquant.comQ
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
November 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/24/3193383/0/en/clearside-biomedical-to-pursue-strategic-sale-of-its-business-through-voluntary-chapter-11-process.html
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
November 14, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2791515/clearside-biomedical-inc-clsd-reports-q3-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2791515
Clearside Biomedical Regains Nasdaq Compliance as of October 2025
October 7, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/clearside-biomedical-regains-nasdaq-compliance-as-of-october-2025?utm_source=marketbeat.com&utm_medium=referral
Clearside Biomedical (CLSD) Price Target Increased by 1,400.00% to 64.26
September 30, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/clearside-biomedical-clsd-price-target-increased-by-140000-to-6426/ar-AA1Nzrdl
Clearside Biomedical Highlights SCS Microinjector® Platform for Retinal Disease Treatment at EURETINA Congress
August 26, 2025  |  quiverquant.comQ
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
August 26, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/26/3139241/0/en/clearside-biomedical-announces-multiple-presentations-on-suprachoroidal-delivery-to-be-featured-at-the-25th-euretina-congress.html
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
August 8, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2685714/clearside-biomedical-inc-clsd-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2685714
Clearside Biomedical stock soars after Health Canada approves XIPERE
July 25, 2025  |  in.investing.comhttps://in.investing.com/news/stock-market-news/clearside-biomedical-stock-soars-after-health-canada-approves-xipere-93CH-4923833
Clearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal Delivery
July 25, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/clearside-biomedical-receives-canadian-approval-for-xipere-to-treat-uveitic-macular-edema-via-suprachoroidal-delivery/ar-AA1J8ACP
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
July 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/23/3120111/0/en/clearside-biomedical-announces-approval-of-xipere-suprachoroidal-treatment-for-uveitic-macular-edema-in-canada.html
HC Wainwright & Co. Downgrades Clearside Biomedical (CLSD)
July 20, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/hc-wainwright-co-downgrades-clearside-biomedical-clsd/ar-AA1IRVAM
Clearside Biomedical Insider Trading Activity | NASDAQ:CLSD | Benzinga
July 18, 2025  |  benzinga.comhttps://www.benzinga.com/quote/CLSD/insider-trades
Chardan Capital Downgrades Clearside Biomedical (CLSD)
July 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/chardan-capital-downgrades-clearside-biomedical-clsd/ar-AA1IRTdh
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
July 18, 2025  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46491314/this-verint-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday
Clearside to Shift Staff to Consultants, Halt R&D, as It Seeks Strategic Alternatives
July 18, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/clearside-to-shift-staff-to-consultants-halt-r-d-as-it-seeks-strategic-alternatives-e56c262d
Needham Downgrades Clearside Biomedical (CLSD)
July 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/needham-downgrades-clearside-biomedical-clsd/ar-AA1IOXWs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$0.67 -0.01 (-1.76%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 +0.03 (+4.02%)
As of 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

BioVie stock logo

BioVie NASDAQ:BIVI

$1.56 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.48 -0.08 (-4.81%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$3.22 -0.23 (-6.78%)
Closing price 03:58 PM Eastern
Extended Trading
$3.40 +0.19 (+5.85%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas